News

Johnson & Johnson (NYSE:JNJ) presented new real-world and clinical data on IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis at the European Academy of Neurology Congress. The data highlighted improved outcomes in patients treated earlier in their disease course and sustained symptom control even after common infections. Additional pregnancy safety monitoring and ongoing trials point to potential use in hard-to-treat and at-risk patient groups beyond the current label. For...

Johnson & Johnson (NYSE:JNJ) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Johnson & Johnson (NYSE:JNJ) announced the commercial launch of the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe. That means the platform is now commercially available to electrophysiologists across the EMEA region for the treatment […]

Johnson & Johnson (NYSE:JNJ) presented new clinical data for IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis at the European Academy of Neurology 2026 Congress. The data focus on earlier use of IMAAVY in the gMG treatment pathway and outcomes for patients with less severe symptoms. The company also highlighted the PETUNIA study, designed to track real-world safety of IMAAVY in pregnancy and maternal and infant outcomes. Johnson & Johnson is building out its profile in rare...

Johnson & Johnson (NYSE:JNJ) is one of Navellier’s top long-term stock picks. On May 12, Johnson & Johnson (NYSE:JNJ) reaffirmed its push for opportunities in the treatment of calcified coronary artery disease, which affects about 315 million people worldwide. The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation intravascular lithotripsy catheter. An […]

The latest generation of the coronary intravascular lithotripsy device is designed to be more flexible to help physicians navigate tight arteries to break up calcified deposits and restore blood flow.